Budesonide orodispersible tablets for maintenance of remission in eosinophilic oesophagitis


Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.

Budesonide orodispersible tablets (Jorveza) are indicated for induction and maintenance of remission in adults with eosinophilic oesophagitis. A NICE technology appraisal recommended budesonide ODT for induction of remission but did not address maintenance. This review assesses the evidence for use in maintenance treatment.

Download the full review below to read more.

Gastro-intestinal System


This report looks at prescribing trends in primary care for for the Gastro-intestinal system at CCG and STP level with particular focus on Dyspepsia, Antisecretory drugs, Acute Diarrhoea, Chronic Bowel Disorders and Laxatives.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net



Data Period

April 2018 to March 2021

This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Inhaler carbon footprint; significance, focus & action

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

The impact of climate change on health is increasing, as global warming continues to rise. 1 Within the health and social care sector, pressurised metered dose inhalers (pMDIs) and breath-actuated pMDIs (BA-pMDIs) have been identified as a significant contributing factor to the NHS carbon footprint.

This publication reviews current inhaler prescribing in the context of global warming potential data, and highlights interventions which should be considered by health systems.

There are three versions of this publication; please select the appropriate version for your region below.

The RDTC has also produced a carbon impact assessment tool for inhalers.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Comparison of LAMA/LABA inhalers (update February 2021)

Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.

Long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs) are available in a variety of combination inhaler devices. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.

For information on the carbon impact of inhalers, see our Prescribing for Population Health publications.

Long-Term Use Of PPIs – Bulletin

Long-term use of PPIs is not recommended in several indications as it has been linked to adverse effects including hypomagnesaemia, vitamin B12 deficiency, increased fracture risk and increased risk of MI.

This bulletin aims to highlight the current national guidance, potential adverse effects associated with long term PPI use and prescribing patterns on a CCG Level.

This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.

There are three versions of this publication; please select the appropriate version for your region below.